Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Exact Sciences

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Eisai launches Halaven in Russia

Expands market reach of its breast cancer drug to cover emerging market

- PMLiVE

FDA panel backs Perjeta in early breast cancer

Unanimous recommendation for use alongside Herceptin

Roche - Basel

Roche wins EU approval for injectable Herceptin

Can reduce cancer drug's administration time from 90 minutes to two minutes

- PMLiVE

AZ launches breast cancer video portal

Pharma company partners with oncology publisher for new HCP resource

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

GSK’s Tyverb cleared for use alongside Herceptin

Combination already approved in the Philippines, Russia and Thailand

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Roche’s Perjeta on US fast-track for early breast cancer

FDA grants priority review for drug's use before surgery

National Institute for Health and Care Excellence NICE logo

UK backs use of drugs to prevent breast cancer

Daily use of tamoxifen or raloxifene recommended in at-risk women

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links